<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-166
Date of Submission: 2025-01-29

This report was submitted by a Patient from Malone, Curtis and Ward Medical Center concerning patient ANON-PX-2944. The subject is an adult female with a significant medical history including type 2 diabetes, seasonal allergies, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Oral route at a dosage of 466mg, initiated on 2024-11-25 for Hypercholesterolemia with the course ongoing; Levothyroxine (Thyroid hormone) administered via the Intramuscular route at a dosage of 216mg, initiated on 2024-11-25 for Hypothyroidism with the course ongoing.

On approximately 2025-01-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Dizziness, Pruritus. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Pruritus was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed friend and advised under. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-166
report_date: '2025-01-29'
patient_details:
  patient_id: ANON-PX-2944
  gender: Female
  relevant_history:
  - type 2 diabetes
  - seasonal allergies
  - osteoarthritis
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 466mg
  route_of_administration: Oral
  start_date: '2024-11-25'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
- drug_name: Levothyroxine
  dosage: 216mg
  route_of_administration: Intramuscular
  start_date: '2024-11-25'
  indication_for_use: Hypothyroidism
  drug_class: Thyroid hormone
adverse_reactions:
- symptom_name: Diarrhea
  onset_date: '2025-01-02'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Dizziness
  onset_date: '2025-01-02'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: false
- symptom_name: Pruritus
  onset_date: '2025-01-02'
  severity: Severe
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed friend and advised under.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Not applicable
  naranjo_score: 3
reporting_facility: Malone, Curtis and Ward Medical Center
reporter_type: Patient
